01/22/2026
Technologies invented by researchers at the Lab’s Center for Industrial & Medical Ultrasound and their multi-institutional collaborators reached a commercial milestone.
SonoMotion announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Break Wave lithotripsy device. The technology licensed from UW and commercialized by SonoMotion non-invasively fragments stones in kidney or ureter on fully awake patients, without anesthesia, and at any site of care.
https://www.prnewswire.com/news-releases/sonomotion-announces-fda-clearance-for-its-break-wave-lithotripsy-device-for-treatment-of-kidney-stones-302666229.html
The team’s research progressed through theoretical and laboratory studies, work in animal models, human feasibility studies, and randomized human clinical trials with results submitted to FDA. The team continues to improve the technologies. Senior Principal Engineer Mike Bailey add, “This technology isn’t just another tool that might work better to treat kidney stones. We are proving that this approved device can access a different set of patients.”
https://www.apl.washington.edu/project/project.php?id=pushing_stones
/PRNewswire/ -- SonoMotion, a venture-backed medical device company developing non-invasive solutions for kidney stones, announced today that it received U.S....